Results 1 to 10 of about 1,456,287 (196)

Analysis of Survival in Complete Pathological Response after Long-Course Chemoradiotherapy in Patients with Advanced Rectal Cancer. [PDF]

Curr Oncol, 2023
Background: Neoadjuvant chemoradiotherapy prior to surgery is the standard treatment for locally advanced rectal cancer. This consists in the patient’s complete pathological response being achieved with no residual tumor presence in the resected specimen,
Ulusoy C, Kamalı GH, Nikolovski A.
europepmc   +2 more sources

Is complete pathological response truly a complete response in breast cancer?

Journal of the Pakistan Medical Association, 2023
Objective: To check if complete pathological response in breast cancer is a good prognostic factor. Method: The retrospective study was conducted at the Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan, and comprised data from January 2012 to December 2015 of all patients who received neo-adjuvant chemotherapy and had no ...
Bushra, Rehman, Sara, Rehman, Sameen, Mohtasham, Toqeer, Zahid, Albash, Sarwar, Muhammad Asad, Parvaiz   +5 more
openaire   +3 more sources

Ability of Delta Radiomics to Predict a Complete Pathological Response in Patients with Loco-Regional Rectal Cancer Addressed to Neoadjuvant Chemo-Radiation and Surgery. [PDF]

Cancers (Basel), 2022
Simple Summary The present study aimed to investigate the possible use of MRI delta texture analysis (D-TA) in order to predict the extent of pathological response in patients with locally advanced rectal cancer addressed to neoadjuvant chemo ...
Nardone V, Reginelli A, Grassi R, Vacca G, Giacobbe G, Angrisani A, Clemente A, Danti G, Correale P, Carbone SF, Pirtoli L, Bianchi L, Vanzulli A, Guida C, Grassi R, Cappabianca S.   +15 more
europepmc   +2 more sources

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. [PDF]

J Immunother Cancer, 2022
Background Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with chemotherapy alone, leading to Food and Drug Administration (FDA) approval of nivolumab plus ...
Casarrubios M, Provencio M, Nadal E, Insa A, Del Rosario García-Campelo M, Lázaro-Quintela M, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé R, Viñolas N, Barneto Aranda I, Massuti B, Sierra-Rodero B, Martinez-Toledo C, Fernández-Miranda I, Serna-Blanco R, Romero A, Calvo V, Cruz-Bermúdez A.   +24 more
europepmc   +2 more sources

Ki-67 and Its Relation With Complete Pathological Response in Patients With Breast Cancer. [PDF]

Cureus, 2021
Introduction Ki-67 is a nuclear antigen present in the synthesis phase of the cell cycle. Studies have shown that a high value of Ki-67 results in greater response to chemotherapy with higher incidence of complete pathological response, which ultimately ...
Wajid S, Samad FA, Syed AS, Kazi F.
europepmc   +2 more sources

Complete pathological response with pembrolizumab in recurrent sigmoid adenocarcinoma. [PDF]

J Surg Case Rep
Genetic evaluation for mismatch repair deficiency (dMMR) or microsatellite instability (MSI) is now routinely performed as part of the workup of colorectal cancer.
Li B, Ma T.
europepmc   +2 more sources

Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in a Patient With Metastatic Intrahepatic Cholangiocarcinoma With High Tumor Mutational Burden. [PDF]

Cureus, 2021
Intrahepatic cholangiocarcinoma (ICC) is an aggressive biliary tract cancer (BTC) with distinct anatomic, molecular, and clinical characteristics.
Abudalou M, Vega EA, Kondratiev S, Conrad C, Kozyreva O.   +4 more
europepmc   +2 more sources

A Meta-Analysis for Using Radiomics to Predict Complete Pathological Response in Esophageal Cancer Patients Receiving Neoadjuvant Chemoradiation. [PDF]

In Vivo, 2021
Background: Preservation of organ function is important in cancer treatment. The ‘watch-and-wait’ strategy is an important approach in management of esophageal cancer.
Kao YS, Hsu Y.
europepmc   +2 more sources

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. [PDF]

Clin Transl Med, 2021
Background Immunotherapy is being tested in early‐stage non‐small cell lung cancer (NSCLC), and achieving higher rates of complete pathological responses (CPR) as compared to standard of care.
Laza-Briviesca R, Cruz-Bermúdez A, Nadal E, Insa A, García-Campelo MDR, Huidobro G, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Casarrubios M, Sierra-Rodero B, Tarín C, Tarín C, García-Grande A, Haymaker C, Wistuba II, Romero A, Franco F, Provencio M.   +28 more
europepmc   +2 more sources

Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer. [PDF]

Oncologist, 2021
Background Patients with colorectal carcinoma and high‐grade microsatellite instability (MSI‐H) or deficiency in mismatch repair (dMMR) exceptionally respond to immune checkpoint inhibitors (ICIs). ICIs are more active in treatment‐naïve patients than in
Trojan J, Stintzing S, Haase O, Koch C, Ziegler P, Demes M, Jelas I.   +6 more
europepmc   +2 more sources